About the Company
We do not have any company description for NKGen Biotech, Inc. at the moment.
Exchange
OTC
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on NKGen Biotech, Inc.
NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC ...
NKGen Biotech, Inc. (“NKGen” or the “Company”) has regained compliance on its public reporting obligations with the filing of its most recent quarterly report on Form 10-Q on March 4, 2025 ...
NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit
NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural ...
NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical ...
SANTA ANA, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization ...
NKGen Biotech Announces Administration of Troculeucel in ... - Nasdaq
NKGen Biotech, Inc., a clinical-stage biotechnology company, has announced the administration of troculeucel, an expanded autologous natural killer (NK) cell therapy, to a patient with ...
NKGen Biotech Announces Administration of First Dose of Troculeucel to ...
SANTA ANA, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and ...
NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a ...
NKGen Biotech, Inc. is developing SNK01 for the treatment of neurodegenerative disorders and a broad range of cancers. About NKGen ...
NKGen Biotech to Present Phase 1 Results on Troculeucel NK ... - Nasdaq
NKGen Biotech, Inc. announced that its CEO, Dr. Paul Y. Song, will present at the upcoming International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna from April 1-5, 2025.
NKGN - NKGen Biotech Inc Dividends | Morningstar
Review the current NKGen Biotech Inc (NKGN:PINX) dividend yield and history to decide if NKGN is the best investment for you.
NKGen Biotech Inc. Wt Research & Ratings | NKGNW | Barron's
NKGen Biotech Inc. Wt research and ratings by Barron's. View NKGNW revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.
NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC ...
Trading commencing on the OTC Markets on March 5, 2025. Trading expected to continue under ticker symbol “NKGN” for common stock and “NKGNW” for warrants. NKGen Biotech, Inc. (NKGN ...
NKGen Biotech, Inc. Announces Dosing of First Patient in its ... - FOX40
NKGen Biotech, Inc. is developing SNK01 for the treatment of neurodegenerative disorders and a broad range of cancers. About NKGen ...
Similar Companies
Loading the latest forecasts...